Evidence map›Paper›PMID 29632364›Full record

ArticleScientific reports2018

Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images.

Donghuan Lu, Karteek Popuri, Gavin Weiguang Ding, Rakesh Balachandar, Mirza Faisal Beg, Alzheimer’s Disease Neuroimaging Initiative

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 5 pooled it
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 5 syntheses or guidelines pooled it, 375 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 20 institutions in 2 countries.

Donghuan LuSchool of Engineering Science, Simon Fraser University, Burnaby, V5A 1S6, Canada.
Karteek PopuriSchool of Engineering Science, Simon Fraser University, Burnaby, V5A 1S6, Canada.
Gavin Weiguang DingSchool of Engineering Science, Simon Fraser University, Burnaby, V5A 1S6, Canada.
Rakesh BalachandarSchool of Engineering Science, Simon Fraser University, Burnaby, V5A 1S6, Canada.
Mirza Faisal BegSchool of Engineering Science, Simon Fraser University, Burnaby, V5A 1S6, Canada. mfbeg@sfu.ca.ORCID 0000-0001-6706-8630
Alzheimer’s Disease Neuroimaging Initiative
New York University · USWashington University in St. Louis · USIndiana University · USNorthwestern University · USUniversity of Alabama at Birmingham · USOregon Health & Science University · USUniversity of California, Davis · USUniversity of California, Irvine · USUniversity of California, Los Angeles · USUniversity of Kentucky · USUniversity of Rochester Medical Center · USUniversity of Southern California · USBaylor College of Medicine · USBoston University · USCornell University · USDuke Medical Center · USMayo Clinic in Florida · USSimon Fraser University · CAStanford University · USWake Forest University · US

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
TR&D3: Intrinsic Surface MappingP41EB015922 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI VAN HORN, JOHN DARRELL · 2012 to 2022
$14.1M
PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential DiagnosisR01AG055121 · NIA · OHIO STATE UNIVERSITY · PI ROSEN, HOWARD J, WANG, LEI · 2017 to 2020
$2.8M
CIHRNIA NIH HHS R01 AG055121NIA NIH HHS U01 AG024904NIBIB NIH HHS P41 EB015922
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disease where biomarkers for disease based on pathophysiology may be able to provide objective measures for disease diagnosis and staging. Neuroimaging scans acquired from MRI and metabolism images obtained by FDG-PET provide in-vivo measurements of structure and function (glucose metabolism) in a living brain. It is hypothesized that combining multiple different image modalities providing complementary information could help improve early diagnosis of AD. In this paper, we propose a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network. Our method delivers 82.4% accuracy in identifying the individuals with mild cognitive impairment (MCI) who will convert to AD at 3 years prior to conversion (86.4% combined accuracy for conversion within 1-3 years), a 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD, and a 86.3% specificity in classifying non-demented controls improving upon results in published literature.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseBrainCase-Control StudiesCognitive DysfunctionDeep LearningEarly DiagnosisFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMiddle AgedMultimodal ImagingNeural Networks, ComputerPositron-Emission TomographyRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID29632364
PMCPMC5890270
OpenAlexW2762081760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.